Table 4.
The results of immunohistochemistry of CNB samples
| IHC | Classification of CNB samples based on morphology, no | ||||
|---|---|---|---|---|---|
| Markers | Results | Indeterminate lesion | Follicular neoplasm | Suspicious for malignancy | Total |
| CK19 | Negative | 9 | 23 | 1 | 33 |
| Positive | 31 | 9 | 34 | 74 | |
| Galectin-3 | Negative | 7 | 12 | 1 | 20 |
| Positive | 33 | 20 | 34 | 87 | |
| HBME-1 | Negative | 16 | 25 | 8 | 49 |
| Positive | 24 | 7 | 27 | 58 | |
| CD56 | Positive | 23 | 26 | 11 | 60 |
| Negative | 17 | 6 | 24 | 47 | |
| IHC-COMB1 | Negative | 17 | 24 | 2 | 43 |
| Positive | 23 | 8 | 33 | 64 | |
| IHC-COMB2 | Negative | 8 | 21 | 2 | 31 |
| Positive | 32 | 11 | 33 | 76 | |
| IHC-COMB3 | Negative | 2 | 10 | 0 | 12 |
| Positive | 38 | 22 | 35 | 95 | |
| Total | 40 | 32 | 35 | 107 | |
CNB, core needle biopsy; IHC, immunohistochemistry; IHC-COMB1, CD56 negative no matter whether CK19, galectin-3, and HBME-1 are positive or not/CD56 positive and all of CK19, galectin-3, and HBME-1 simultaneously positive; IHC-COMB2, CD56 negative no matter whether CK19, galectin-3, and HBME-1 are positive or not/CD56 positive and at least two of CK19, galectin-3, and HBME-1 simultaneously positive; IHC-COMB3, CD56 negative no matter whether CK19, galectin-3, and HBME-1 are positive or not/CD56 positive and at least one of CK19, galectin-3, and HBME-1 simultaneously positive